PubRank

Guosheng Yin

Author PubWeight™ 29.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 2010 1.69
2 ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006 1.66
3 HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009 1.61
4 Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 2007 1.54
5 Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. Clin Cancer Res 2012 1.33
6 Sequential continual reassessment method for two-dimensional dose finding. Stat Med 2008 1.28
7 Marginal analysis of correlated failure time data with informative cluster sizes. Biometrics 2007 1.22
8 Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006 1.20
9 BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. Ann Appl Stat 2011 1.17
10 Root canal filled versus non-root canal filled teeth: a retrospective comparison of survival times. J Public Health Dent 2005 1.09
11 Robust EM Continual Reassessment Method in Oncology Dose Finding. J Am Stat Assoc 2011 1.03
12 Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008 1.03
13 Bayesian hybrid dose-finding design in phase I oncology clinical trials. Stat Med 2011 0.99
14 Dose-response curve estimation: a semiparametric mixture approach. Biometrics 2011 0.98
15 Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. Cancer 2010 0.97
16 Bayesian quantile regression for longitudinal studies with nonignorable missing data. Biometrics 2009 0.97
17 Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 2007 0.93
18 Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest 2010 0.92
19 Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 2005 0.90
20 Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials 2013 0.90
21 On the usefulness of outcome-adaptive randomization. J Clin Oncol 2011 0.90
22 Escalation with overdose control for phase I drug-combination trials. Stat Med 2013 0.87
23 Efficiency improvement in a class of survival models through model-free covariate incorporation. Lifetime Data Anal 2011 0.82
24 Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist 2011 0.82
25 Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Anal 2010 0.81
26 Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer. Mod Pathol 2006 0.81
27 Phase I trial design for drug combinations with Bayesian model averaging. Pharm Stat 2015 0.78
28 Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Anal 2012 0.75
29 Generalized partially linear single-index model for zero-inflated count data. Stat Med 2014 0.75